Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples